澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - adalimumab, quantity: 100 mg/ml - injection, solution - excipient ingredients: polysorbate 80; water for injections; mannitol - rheumatoid arthritis: humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis: - polyarticular juvenile idiopathic arthritis: humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (dmards). humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. - enthesitis-related arthritis: humira is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis: humira is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis: humira is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.,crohn's disease in adults and children (6 years and older): humira is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients; - who have had an inadequate response to conventional therapies or, - who have lost response to or are intolerant of infliximab.,ulcerative colitis: humira is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see clinical trials).,psoriasis in adults and children: humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age): humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis: humira is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - adalimumab, quantity: 100 mg/ml - injection, solution - excipient ingredients: mannitol; polysorbate 80; water for injections - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.,,juvenile idiopathic arthritis humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying antirheumatic drugs (dmards). humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis humira is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis humira is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis humira is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.,crohn?s disease in adults and children (?6 years) humira is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients; - who have had an inadequate response to conventional therapies or, - who have lost response to or are intolerant of infliximab.,ulcerative colitis humira is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see clinical trials).,psoriasis in adults and children humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age) humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis: humira is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - adalimumab, quantity: 100 mg/ml - injection, solution - excipient ingredients: mannitol; polysorbate 80; water for injections - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying antirheumatic drugs (dmards). humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis humira is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis humira is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis humira is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.,crohn?s disease in adults and children (?6 years) humira is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients; - who have had an inadequate response to conventional therapies or, - who have lost response to or are intolerant of infliximab.,,ulcerative colitis humira is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see clinical trials).,psoriasis in adults and children humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age) humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis humira is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - chlorhexidine acetate, quantity: 0.15 mg/ml; cetrimide, quantity: 1.5 mg/ml - solution, irrigation - excipient ingredients: water for injections; glacial acetic acid; tartrazine - chlorhexidine acetate (0.015 %) with cetrimide (0.15 %) antiseptic solution is used as a general antiseptic. it is used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 9000 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 900 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 3600 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 1800 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

1%) solution for injection ampoules (advanz pharma - lidocaine hydrochloride - solution for injection - 10mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

1%) solution for injection ampoules (advanz pharma - lidocaine hydrochloride - solution for injection - 10mg/1ml